title: Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia.
authors.forename: Albert
authors.initials: A
authors.lastname: Deisseroth
authors.forename: Ann
authors.initials: A
authors.lastname: Farrell
authors.forename: Robert
authors.initials: R
authors.lastname: Justice
authors.forename: Robert
authors.initials: R
authors.lastname: Kane
authors.forename: Rajeshwari
authors.initials: R
authors.lastname: Sridhara
authors.forename: Huanyu
authors.initials: H
authors.lastname: Chen
authors.forename: Kun
authors.initials: K
authors.lastname: He
authors.forename: Richard
authors.initials: R
authors.lastname: Pazdur
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage / Q000009:adverse effects*; D007262:Infusions, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000964:Antimetabolites, Antineoplastic; D006834:Hydrazines; D013449:Sulfonamides; D003561:Cytarabine; C483604:laromustine